To the full analysis
Buyback calculator for Orchestra BioMed Holdings
Orchestra BioMed Holdings stock: key metrics
OBIOOrchestra BioMed Holdings had an operating margin of −154.7% and a return on invested capital (ROIC) of −51.8% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2020 | 97.5% | −328.8% | −374.5% |
| 2021 | no data | no data | no data |
| 2022 | 90.9% | −924.3% | −951.3% |
| 2023 | 93.3% | −1,866.2% | −1,779.7% |
| 2024 | 92.3% | −2,437.5% | −2,313.3% |
| 2025 | 99.4% | −154.7% | −157.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2020 | 44.0% | −53.4% | −56.1% |
| 2021 | 32.3% | no data | −100.0% |
| 2022 | −64.0% | −64.3% | −35.2% |
| 2023 | −72.2% | −50.5% | −51.6% |
| 2024 | −100.0% | −70.6% | −80.1% |
| 2025 | −83.2% | −51.8% | −45.9% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 13 Nov 2026, previously Weak
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.